> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Praxis Stock Soars 10% After Earnings — Its Quarterly Loss Widens
- URL: https://www.bullished.co/praxis-stock-soars-10-after-earnings-its-quarterly-loss-widens-c64b500c/
- Published: 2026-11-09T15:35:20.000Z
- Updated: 2026-11-09T15:35:20.000Z
- Description: The drug developer has approximately $1.3 billion in cash and investments and is preparing for potential launches while FDA reviews remain pending.
- Author: Matteo Parrino
- Tags: Markets, PRAX, Industry: Healthcare

[Praxis Precision Medicines](https://www.bullished.co/tag/prax/), which develops treatments for epilepsy and movement disorders, soared 10.34% to $306.32 in Monday trading, as of 10:32 a.m. ET, adding $801 million in market value after its earnings report. Its Monday corporate update detailed [launch preparations](https://www.globenewswire.com/news-release/2026/11/09/3398230/0/en/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2026-financial-results.html?ref=bullished.co) while FDA reviews remained pending for essential-tremor treatment ulixacaltamide and epilepsy treatment relutrigine.

## Launch Hiring Meets Wider Losses

Praxis is preparing for potential drug launches. Marcio Souza, president and CEO of Praxis Precision Medicines, said: "The relutrigine team [is fully hired](https://www.globenewswire.com/news-release/2026/11/09/3398230/0/en/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2026-financial-results.html?ref=bullished.co)".

The third-quarter [loss widened](https://www.sec.gov/Archives/edgar/data/0001689548/000168954826000086/prax-20261109.htm?ref=bullished.co) to $94.2 million from $73.9 million a year earlier. Stock-based compensation increased to $14.9 million from $7.4 million.

Praxis had approximately [$1.3 billion](https://www.globenewswire.com/news-release/2026/11/09/3398230/0/en/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2026-financial-results.html?ref=bullished.co) in cash and investments at quarter-end. Management expects that money to fund operations into 2028.

## An Epilepsy And Tremor Pipeline

Praxis uses genetic insights to develop medicines targeting imbalances in brain-cell activity. Its Cerebrum platform focuses on oral drugs; Solidus develops antisense oligonucleotides, medicines intended to change gene expression.

Its clinical-stage pipeline comprises four candidates. Alongside ulixacaltamide, relutrigine and elsunersen target severe genetic epilepsies, while vormatrigine targets common epilepsies.

Licensing agreements also form part of the business. UCB licensed PRAX-020, and Tenacia Biotechnology has an exclusive collaboration and license to develop and commercialize ulixacaltamide in China, Hong Kong, Macau and Taiwan.

## A Rebound From Underperformance

Monday's advance put PRAX shares on pace for their biggest one-day gain since Aug. 6\. Praxis's market value stood at about $8.6 billion in Monday trading.

Through Friday's close, the stock had lost 6% this year while the S&P 500 had gained 8%. Shares finished Friday 28% below their highest closing price of the past year.

Continuing losses were already part of that backdrop: Praxis reported a second-quarter [net loss](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000083/prax-20260630.htm?ref=bullished.co) of $83.7 million.

Praxis is scheduled to hold its Investor Day on Thursday, with commercial strategy, launch readiness and its drug-development pipeline on the agenda.

### Sources

- [Praxis Precision Medicines Non-GAAP EPS of -$3.23 beats by $0.40 (PRAX:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4668884-praxis-precision-medicines-non-gaap-eps-of-3%5F23-beats-by-0%5F40?ref=bullished.co) — seekingalpha.com
- [Praxis Precision Medicines Provides Corporate Update and](https://www.globenewswire.com/news-release/2026/11/09/3398230/0/en/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com
- [The company's filing (Praxis Precision Medicines)](https://www.sec.gov/Archives/edgar/data/0001689548/000168954826000086/prax-20261109.htm?ref=bullished.co) — SEC filing
- [Praxis Precision Medicines — Form 10-Q for the quarter ended 2026-06-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000083/prax-20260630.htm?ref=bullished.co) — SEC EDGAR

### More on Praxis Precision Medicines

- [Praxis Administrative Spending Reaches $42.7 Million As It Prepares For Potential Drug Launches](https://www.bullished.co/praxis-administrative-spending-reaches-42-7-million-as-it-prepares-for-potential-drug-82a27b57/)

[All Praxis Precision Medicines (PRAX) coverage →](https://www.bullished.co/tag/prax/)